Measuring Health-Related Quality of Life in Leukemia: The Functional Assessment of Cancer Therapy – Leukemia (FACT-Leu) Questionnaire  by Cella, David et al.
Avai lable onl ine at www.sc iencedirect .comVA L U E I N H E A LT H 1 5 ( 2 0 1 2 ) 1 0 5 1 – 1 0 5 81098-3015 – see fro
Published by Elsevie
http://dx.doi.org/10
E-mail: d-cella@
* Address correspo
Abbott Hall, 710 Nojournal homepage: www.elsevier .com/ locate / jva lMeasuring Health-Related Quality of Life in Leukemia: The Functional
Assessment of Cancer Therapy – Leukemia (FACT-Leu) Questionnaire
David Cella, PhD1,2,*, Sally E. Jensen, PhD1,4, Kimberly Webster, MA1, Hongyan Du, MS3, Jin-Shei Lai, PhD1,2,
Steven Rosen, MD2, Martin S. Tallman, MD5, Susan Yount, PhD1,2
1Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA; 2Robert H. Lurie Comprehensive Cancer Center
of Northwestern University, Chicago, IL, USA; 3Center for Clinical Research Informatics, NorthShore University HealthSystem, Evanston, IL, USA; 4Division of
Organ Transplantation, Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, USA; 5Leukemia Service, Department of
Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
A B S T R A C TObjective: Develop and validate a health-related quality-of-life
(measure for patients with acute and chronic leukemia. Methods:
The study consisted of two phases: scale construction and scale
validation. For the item-generation phase, a summary of the literature
combined with qualitative results from item-generation interviews
with 29 acute or chronic leukemia patients and 16 health care
providers yielded an initial item pool reflecting leukemia-specific
concerns and symptoms. Items underwent iterations of review and
reduction according to defined retention criteria to support content
validity, as defined by priority concerns of patients. Seventeen final
leukemia-specific items were combined with the Functional Assess-
ment of Cancer Therapy–General to create the FACT-Leukemia (FACT-
Leu) scale. For the validation phase, 79 individuals with acute or
chronic leukemia completed questionnaires at three time points.
Results: All FACT-Leu subscale and aggregated scores showed highnt matter Copyright & 2012, International Society
r Inc.
.1016/j.jval.2012.08.2210
northwestern.edu.
ndence to: David Cella, Department of Medical Soci
rth Lake Shore Drive, 7th Floor, Chicago, IL 60611internal consistency (as ranging from 0.75 to 0.96). Test-retest relia-
bility was adequate for all subscales (intraclass correlation range
0.765–0.890). The FACT-Leu scale demonstrated good convergent
validity, with significant correlations with quality-of-life criteria and
performance status, in the expected direction. FACT-Leu subscale
scores were significantly different among the three performance
status change groups, suggesting good responsiveness to change.
Conclusions: The FACT-Leu scale is a valid, reliable, and efficient
measure of leukemia-specific health-related quality of life for acute
and chronic disease.
Keywords: acute leukemia, chronic leukemia, health-related quality of
life, patient-reported outcomes.
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Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
In 2012, leukemia is estimated to account for 47,150 new cases
and 23,540 deaths in the United States [1]. While the clinical
management of hematologic malignancies has improved over
the past 50 years, cures remain elusive [2–5]. The addition of
treatment options and a better understanding of factors predict-
ing treatment response have improved the 1- and 5-year relative
survival rates but have also introduced toxicities that can offset
clinical benefit [4,6]. In cases where the chance for cure is low
(e.g., acute myeloid leukemia) and available treatments have a
questionable impact on survival and known toxicity/cost, health-
related quality of life (HRQOL) becomes an even more important
clinical management concern.
HRQOL concerns in leukemia may vary depending on prog-
nosis (and related therapeutic intent), disease-specific concerns,
and treatment-specific concerns [6]. Primary concerns may
include disease symptoms, treatment toxicity, increased risk of
second malignancy, long-term and late effects of treatment (e.g.,fatigue), and treatment decision making. Because of the pro-
longed course and risk of life-threatening or disrupting treat-
ments, patients with leukemia have concerns about their
mortality, loss of independence, disfigurement, life disruption,
and disability [7–9]. Concerns related to living with uncertainty
and the ‘‘emotional exhaustion’’ due to the potentially long-term
disease course, financial burden, increased risk for depressive
mood and anxiety, sexual functioning, interference, and family
disruption are also significant [9–11]. Stem cell transplantation
also confers risks for acute and chronic graft-versus-host disease,
infection, endocrine disturbances, fatigue, and cognitive dysfunc-
tion [12].
Although HRQOL concerns of patients with acute and chronic
leukemia have been reported, few validated instruments mea-
sure them concisely [13–15]. This has been cited as a factor
limiting the use of HRQOL as an end point in leukemia treatment
research [16]. Very few clinical trials in leukemia, acute or
chronic, have included a study of HRQOL [17]. Those which
have tended to use general measures such as the Europeanfor Pharmacoeconomics and Outcomes Research (ISPOR).
al Sciences, Northwestern University Feinberg School of Medicine,
, USA.
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Quality of Life Core Questionnaire 30 [18,19] and the Functional
Assessment of Cancer Therapy-General (FACT-G [20,21]). Avail-
able disease-specific questionnaires include the Life Ingre-
dient Profile for hematologic malignancies [22], and the
Medical Research Council/EORTC Quality of Life Questionnaire-
Leukaemia Module (MRC/EORTC QLQ-LEU [14]), a measure of
HRQOL for individuals with leukemia in long-term remission.
Two additional EORTC leukemia-specific modules—the EORTC
Quality of Life Module for Chronic Lymphocytic Leukaemia [23]
and the EORTC Module for Chronic Myeloid Leukaemia [24]—are
currently in development; however, validity data have not been
published.
As international collaboration in clinical research has increased,
so has the need for cross-culturally relevant patient outcome
assessments. International applicability could be enhanced if an
HRQOL questionnaire specific to leukemia underwent a parallel
cross-cultural development approach to ensure semantic equiva-
lence and cultural relevance [25,26]. The purpose of this study was
to develop and examine the preliminary validity of a questionnaire
developed with cross-cultural input, to measure the HRQOL of
patients with acute and chronic leukemia.Methods
Study Design
The development and validation of the FACT-Leukemia (FACT-
Leu) scale consisted of two stages: 1) scale construction (item
generation and scale construction) and 2) scale validation
(reliability/validity testing). All patients in both stages provided
informed consent for participation. This study was conducted in
compliance with all relevant local institutional review boards.
Scale Construction
Participants
A purposive sample of 29 patients (19 acute, 10 chronic) from
seven countries (Argentina, Brazil, France, Germany, Poland,
Russia, and the United States) and 16 health care providers from
nine countries (above plus Greece and Uruguay) participated in
item generation and scale construction. This portion of the study
was conducted under local institutional review board approval
that included a contractual agreement with the international
sites that only de-identified data would be transmitted. There-
fore, demographic data are not available. The number of patients
and providers in the item-generation phase exceeds the number
of cases typically required (12–15) for saturation in qualitative
research [27–29]. Given the inclusion of acute and chronic
leukemia and the possibility that each would manifest with
unique sets of symptoms and concerns, we estimated an item-
generation sample size of up to 30 patients. Saturation was met
prior to this goal as determined by the centralized project
manager who noted that no new content was coming in the last
several interviews.
Providers (nine physicians and seven nurses) were leukemia
specialists with a range of 3 to 45 years of experience in
hematology/oncology and hematopoietic cell transplantation.
Eligible providers were sufficiently proficient in English for inter-
views and completion of forms. Providers were recruited at two
international leukemia investigator meetings: one sponsored by
the US National Cancer Institute and the other sponsored by a
pharmaceutical company. Patients were recruited by the investi-
gators at their home institutions and then interviewed by our
trained instrument development interviewers and language
translation professionals.Procedures
Experts and patients were interviewed individually by trained
researchers by using a semi-structured item-generation inter-
view designed to elicit patient experiences and expert opinions
and observations regarding how leukemia may affect physical
status, emotional well-being, functional well-being, family /social
issues, sexuality/intimacy, work status, and future orientation.
According to Functional Assessment of Chronic Illness Therapy
item-generation standard practice, each patient interview began
with a nondirective, open-ended inquiry as to the most impor-
tant HRQOL concerns associated with leukemia and its treatment
[30]. Experts were also asked to comment on whether acute and
chronic disease questionnaires should be separate or combined
into one common instrument.
In addition to the above, we conducted a literature search to
identify additional HRQOL issues. We performed a MEDLINE
search of English language studies from 2000 to 2002 by using
the search terms ‘‘acute leukemia’’ and ‘‘chronic leukemia.’’
Articles were retained for review if they addressed physical,
functional, social, or emotional aspects of acute or chronic
leukemia. A summary of the 24 articles selected, combined with
qualitative data collected from patients and experts, was used to
generate items reflecting unique symptoms/concerns related to
leukemia.
Source data were summarized individually and then collec-
tively by leukemia subtype (chronic vs. acute). Symptoms and
concerns were grouped according to preset HRQOL domains and
tracked according to the frequency each one was referenced, by
source. This created an initial item pool. Items underwent
iterations of review and reduction according to defined retention
criteria. The selection criteria included all items referenced at a
cumulative (patient, expert, literature) frequency of 10% or
greater for physical symptoms and 15% or greater for all other
problems/issues for both the chronic and acute subtypes.
Retained items were then presented to 15 of the 16 international
clinical experts who participated in the item-generation phase
for more detailed ratings of symptom prevalence and degree of
concern by leukemia subtype. Each item was rated for each
subtype on two 0 to 3 scales (‘‘0’’ ¼ not at all common/not at all
a concern to ‘‘3’’ ¼ very common/very much of a concern’’).
Expert review of these 53 items was summarized by subtype
and used in combination with the summarized patient data to
derive content for the scale that would go to initial validity
testing. Items with a median expert rating of greater than or
equal to 2 (either for how common a symptom it is or how much
of a concern the symptom is) plus a frequency of more than 15%
across both subtypes were retained. During a final review, item
wording was refined to produce the test version of the leukemia
subscale. Special attention was given to whether a common
(acute and chronic) or separate (acute vs. chronic) subscale would
be optimal. This was explored during the initial item-generation
interviews and addressed in all iterations of review during scale
construction. For quality and clarity, an internal team with
extensive expertise in self-report scale development (composed
of two allied health professionals with clinical mental health
experience treating leukemia, one psychometrician, one statisti-
cian, one cross-cultural and language translation expert, and a
qualitative researcher) navigated the development process and
reviewed and edited final subscale items for wording (semantic
simplicity), cross-cultural relevance, and translatability.
Scale Validation
Participants
A convenience sample of 79 men and women recruited from
oncology clinics at three Chicago-area hospitals participated in
the reliability and validity testing. We estimated that a minimum
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associations (Pearson correlation coefficient ¼ 0.38) between the
FACT-Leu subscales and other instruments, to assess convergent
validity, and to detect effect sizes (ESs) of 0.66 or more when
comparing clinically distinct groups or meaningful change over
time. This number was also selected as the minimum sample
size required for achieving a stable estimate of correlations
between FACT-Leu subscales and other related scales and a stable
estimate of test-retest reliability. After opening the study, we
increased the target sample to 80, primarily to increase power to
detect FACT-Leu scale score differences between clinically dis-
tinct groups and change over time.
Eligible participants were aged 18 years or older, at least 2
months postdiagnosis of any type or stage of leukemia, had a life
expectancy of more than 3 months, and English fluency sufficient
to be interviewed and complete forms. Exclusion criteria
included a diagnosis of psychosis or dementia. Table 1 provides
the sociodemographic and disease characteristics of this scale
validation sample.
Procedures
Participants (n ¼ 79) completed an assessment battery of self-
report measures (described below) at baseline (T1), the 44-item
FACT-Leu scale 3 to 7 days later (T2), and a repeat of the full
battery 8 to 12 weeks after the initial assessment (T3). The
purpose of T2 was to evaluate subscale stability (test-retest
reliability), and the purpose of T3 was to evaluate responsivenessTable 1 – Validation sample characteristics (n ¼ 79).
n %
Age (y)
Mean  SD 60.1  15.7
Median (range) 61 (21–89)
Gender
Male 44 56
Female 35 44
Race/ethnicity
White 72 91
Black 3 4
Hispanic/Latino 2 2.5
Southeast Asian 2 2.5
Type of leukemia
Acute 44
AML 27
ALL 5
APML 3
Chronic 56
CLL 25
CML 15
Hairy cell 4
ECOG Performance status rating
Normal activity, no symptoms 35 44
Some symptoms, no bed rest 30 38
Some amount of bed rest 14 18
On treatment
Chemotherapy 30 38
None 49 62
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia;
APML, acute promyelocytic leukemia; CLL, chronic lymphocytic
leukemia; CML, chronic myelogenous leukemia; ECOG, Eastern
Cooperative Oncology Group.
* Some patients may be receiving natural medicines or supportive
care measures.to change. T1 and T3 assessments also provided preliminary data
on concurrent (convergent and divergent) validity.
Measures
At baseline, participants completed a battery of paper and pencil
self-report measures including the FACT-G [20] and the 27-item
Leu subscale. The FACT-Leu scale (FACT-G þ Leu subscale) has
multiple scoring options that reflect different approaches to
examining HRQOL, including the FACT-G subscales (Functional
Well-being, Social Well-being, Emotional Well-being, Physical
Well-being, the Leu subscale, the total FACT-Leu scale score,
and the trial outcomes index ¼ Physical Well-being þ Functional
Well-being þ Leu subscale). Additional self-report measures were
included in the battery to examine concurrent validity. The
Profile of Mood States-Short Form [31], a measure of transient
mood states, and MRC/EORTC QLQ-LEU [14] were administered to
examine convergent validity. The MRC/EORTC QLQ-LEU is not
listed as a validated module by the EORTC; however, at the time
of this study, the MRC/EORTC QLQ-LEU was the only available
instrument designed specifically to assess HRQOL in leukemia.
The Marlowe-Crowne Social Desirability Scale [32], a measure of
the extent to which individuals present themselves favorably,
was administered to examine divergent validity. The Eastern
Cooperative Oncology Group self-rated performance status rating
scale was administered to examine responsiveness to change.
To re-examine content validity, at the end of T1, patients were
asked to review and comment on the item clarity and meaning,
relevancy, and missing content of each item of the FACT-Leu
scale. At T2, participants completed only the FACT-Leu scale. At
the T3 assessment, participants completed the T1 battery of
measures and a Global Rating of Change Scale (adapted from
[33]). At T1 and T3, clinical data were obtained from chart review.
Statistical considerations
To address scale refinement, an exploratory principal compo-
nents factor analysis of the 27 leukemia items estimated dimen-
sionality and scoring direction. Internal consistency reliability of
subscale and total scores was assessed by using Cronbach’s
coefficient alpha. Spearman’s correlation coefficients were used
to assess the strength of relationships between the FACT-Leu
scale and the Marlowe-Crowne Social Desirability Scale, the
Profile of Mood States-Short Form, and the MRC/EORTC QLQ-LEU
at each time point. Patients were divided into three performance
status groups: 0, normal functioning, without symptoms; 1, some
symptoms but no extra rest required; and 2 to 4, some degree of
bed rest needed during the waking day. Mean FACT-Leu subscale
and aggregated scores were compared between performance
status groups by using analysis of variance. Scores were also
compared between groups of patients defined by treatment
status (current chemotherapy or radiation vs. no or other treat-
ment) and disease type (acute vs. chronic) by using 2-sample
t tests. To assess the sensitivity to change over time, change in
each of the subscales of the FACT-Leu scale was computed. Three
performance status change groups were defined: improved,
worsened, and unchanged. Analysis of variance models were
used to compare the mean FACT-Leu scale change scores
between groups.Results
Scale Construction
The literature summary and qualitative data produced 215
unique symptoms or concerns (182 for acute leukemia and 154
for chronic leukemia, with significant overlap). Concerns covered
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53 was retained for further evaluation. Of these, 38 items were
commonly referenced by both acute and chronic patients; 15
concerns were preserved on the basis of their cumulative fre-
quency of referencing by one subtype or the other. The 53 items
were further reduced to 42 on the basis of low patient and expert
relevance or importance ratings (six items), redundancy (two
items), or lack of specificity to leukemia (three items). A few other
items were also considered for retention because the cumulative
or patient-reported frequency of the item was greater than 15%
by one subtype, even though the median expert rating fell below
2 (e.g., ‘‘headaches’’ for acute patients and ‘‘nausea/vomiting’’ for
chronic patients). Following additional reviews, the list was
further reduced to 27 items. Items deleted included those that
overlapped with the FACT-G, those that did not reflect issues that
could reasonably be attributed as leukemia specific (too general),
or those that could be collapsed into or captured by a very similar
question already included. This final subscale includes 17 physi-
cal symptoms (fevers, bleeding, general pain, stomach area pain,
chills, night sweats, bruising, lymph node lumps/swelling, weak-
ness, tiredness, weight loss, appetite, shortness of breath, func-
tional ability, diarrhea, concentration, and mouth sores) and 10
emotional/social concerns (frustration with activity limitation,
discouraged by illness, future planning, uncertainty, worry about
illness, emotional ups and downs, isolation, concern about
infertility, worry about family, and worry about infections).
Most (69%) experts believed that separate subscales for acute
and chronic leukemia would be ideal. Their reasoning was based
on different natural histories, treatment schedules, and prog-
noses across subtypes. However, because of the extensive overlap
of top priority disease-specific items across acute and chronic
leukemia, we pooled these common items into a common
leukemia scale. The 27-item Leu subscale was formatted accord-
ing to a five-point Likert scale (‘‘0’’ ¼ not at all, ‘‘1’’ ¼ a little bit,
‘‘2’’ ¼ somewhat, ‘‘3’’ ¼ quite a bit, and ‘‘4’’ ¼ very much) and
combined with the 27-item FACT-G to create a 54-item first-
generation FACT-Leu scale for reliability and validity testing
(results described below).
Scale Validation
Most participants found the FACT-Leu scale minimally burden-
some to complete and typically completed it within 5 to 15
minutes. Patient content validity feedback on the FACT-Leu scale
was generally positive, confirming face and content validity with
regard to the inclusion of highest priority content. The majority
of patients said that the items were relevant, comprehensive, and
easy to understand. Positive comments about leukemia items
included ‘‘excellent,’’ ‘‘easy to understand and covered a lot,’’
‘‘valid and appropriate,’’ ‘‘these issues are significant,’’ and
‘‘insightful into the emotional experiences.’’ No participant found
the items difficult to understand or unclear, although one
participant said that they were too vague. A few people com-
mented on the relevancy of non–leukemia-specific items from
the FACT-G. Two people also said that items were most relevant
to the period when they were diagnosed or undergoing treat-
ment. Feedback on missing content included questions about
symptoms associated with medication, appointments, insurance,
attitude, and cost. These content areas had been raised in the
item development phase but without sufficient relevance or
importance ratings to warrant inclusion in an abbreviated scale
to capture the most important disease-specific concerns of
patients with leukemia.
Subscale refinement
We performed an exploratory principal components factor ana-
lysis of the 27 leukemia items to estimate dimensionality andscoring direction. Ten items were eliminated for the following
reasons: too generic (three items: trouble concentrating, fru-
strated by being unable to do the things I want to do, and worry
about ability to support family); highly related/redundant to other
items in the scale (one item: discouraged about my illness); or
very low factor loading on the dominant single factor (six items:
discomfort or pain in my stomach area, shortness of breath,
diarrhea, difficulty planning for future, mouth sores, and ability
to have children). Reliability and validity data reported here
reflect analysis of the 17-item scale.
Reliability
All FACT-Leu subscale and aggregated scores showed high inter-
nal consistency at T1, T2, and T3 assessments (Table 2). The
17-item Leu subscale score demonstrated good internal consistency
for the combined acute/chronic sample: a ¼ 0.86 (T1), 0.88 (T2), and
0.87 (T3). Test-retest reliability was evaluated by comparing FACT-
Leu scale scores between T1 and T2 by using an intraclass
correlation coefficient (Table 2).
Convergent and divergent validity
Correlations with Profile of Mood States-Short Form total score
were, as predicted, fairly high. Those with the FACT-G and FACT-
Leu scale total scores exceeded 0.70 (Table 3). The Marlowe-
Crowne Social Desirability Scale was included to demonstrate
divergent validity (i.e., no significant relationship should exist
between social desirability and self-reported quality of life).
Although there was some evidence of a statistically significant
association between FACT-Social/Family Well-being and social
desirability, the magnitude of the coefficient (0.34) was modest.
All other divergent validity coefficients (including with the Leu
subscale) were nonsignificant, as predicted.
All FACT-Leu subscale and aggregated scores showed pre-
dicted differences in means on the basis of patient performance
status, with higher scores associated with better self-reported
health (Table 4). ESs of score differences by performance status
category ranged from small to very large, with the vast majority
(21 of 24 comparisons) being medium or larger (ES4 0.5). Speci-
fically, the 17-item Leu subscale discriminated these three groups
from one another (ES range ¼ 0.90–1.75).
Among participants, Physical Well-being, Leu subscale, FACT-
Leu scale (total), and trial outcomes index showed differences in
means on the basis of treatment on/off status, with a lower mean
score associated with being on treatment (Table 5). None of the
subscales or aggregated scores showed differences in means of
acute patients and chronic patients, except for Social Well-being
with a lower mean score in chronic patients (Table 6).
Responsiveness to change
Changes in FACT-Leu subscale scores were significantly different
among the three performance status change groups. Patients
who rated themselves as worse had worsening scores on many
subscales and the overall score, patients who improved tended to
have improvements in their subscales and the overall score, and
patients who remained the same tended to have change scores
for most subscales and overall score that were in between the
two other groups (Table 7).Conclusions
We report on the development and initial validation of a FACT
leukemia-specific subscale that measures the most common and
important HRQOL concerns of people with leukemia. The Leu
subscale was developed by using a rigorous multistep methodol-
ogy to assess leukemia-specific HRQOL concerns of individuals
Table 2 – Descriptive and reliability statistics for the FACT-Leu scale.
Mean  SD Range Cronbach’s alpha ICC
PWB
Time 1 (n ¼ 77) 22.7  5.8 2–28 0.89
Time 2 (n ¼ 66) 22.0  6.2 6–28 0.89 0.765
Time 3 (n ¼ 61) 23.1  5.0 7–28 0.84
SWB
Time 1 (n ¼ 77) 23.2  5.5 7–28 0.87
Time 2 (n ¼ 66) 22.6  5.3 8–28 0.85 0.854
Time 3 (n ¼ 61) 22.7  5.5 0–28 0.84
EWB
Time 1 (n ¼ 76) 18.7  4.0 8–24 0.77
Time 2 (n ¼ 66) 18.5  3.9 8–24 0.75 0.834
Time 3 (n ¼ 62) 18.7  4.5 7–24 0.80
FWB
Time 1 (n ¼ 76) 19.7  5.9 6–28 0.83
Time 2 (n ¼ 66) 19.3  5.5 6–28 0.83 0.774
Time 3 (n ¼ 62) 20.1  5.1 11–28 0.81
FACT-G
Time 1 (n ¼ 76) 84.3  15.8 46–108 0.92
Time 2 (n ¼ 66) 82.4  16.7 45–108 0.93 0.806
Time 3 (n ¼ 61) 85.0  15.4 47–107 0.93
Leu subscale
Time 1 (n ¼ 77 ) 51.6  10.4 17–68 0.86
Time 2 (n ¼ 66) 51.0  11.6 10–68 0.88 0.890
Time 3 (n ¼ 62) 53.2  9.7 25–66 0.87
FACT-Leu scale
Time 1 (n ¼ 76) 135.9  25.0) 63–176 0.95
Time 2 (n ¼ 66) 133.4  27.0 69–176 0.95 0.861
Time 3 (n ¼ 61) 138.4  23.8 78–172 0.96
TOI
Time 1 (n ¼ 76) 94.0  20.3) 25–124 0.94
Time 2 (n ¼ 66) 92.3  21.6 38–124 0.94 0.868
Time 3 (n ¼ 61) 96.9  18.1 50–122 0.94
Note: Although 79 participants enrolled and provided demographic data, 1 participant subsequently withdrew, a second participant provided
no FACT-Leu scale data at any time point, and a third participant provided partial FACT-Leu data, reflecting baseline FACT-Leu scale data from
76 to 77 participants. EWB, Emotional Well-being; FWB, Functional Well-being; FACT-G, PWB þ SWB þ EWB þ FWB; FACT-Leu, FACT-G þ Leu
subscale; TOI, trial outcome index, PWB þ FWB þ Leu subscale; ICC, intraclass correlation coefficient between assessment 1 and assessment 2;
Leu, Leukemia subscale; PWB, Physical Well-being; SWB, Social/Family Well-being.
Table 3 – Convergent and divergent validity of the FACT-Leu scale at baseline (Spearman correlation coefficients).
PWB SWB EWB FWB FACT-G Leu
subscale
FACT-Leu
scale
TOI
MCSDS (n ¼ 75) 0.01 0.34 0.23 0.00 0.14 0.10 0.14 0.05
MRC/EORTC QLQ-LEU (n ¼ 69)
GVHD 0.64† 0.28 0.30 0.46† 0.52† 0.63† 0.60† 0.64†
INFECT 0.44 0.19 0.15 0.43 0.41 0.46† 0.45 0.50†
SENSLOSS 0.57† 0.07 0.08 0.55† 0.43 0.42 0.46† 0.55†
FUNCTION 0.47† 0.05 0.10 0.41 0.36 0.29 0.36 0.41
POMS (n ¼ 75)
Tension/anxiety 0.48† 0.33 0.67† 0.56† 0.67† 0.59† 0.67† 0.61†
Depression/dejection 0.44† 0.29 0.64† 0.60† 0.65† 0.62† 0.66† 0.62†
Fatigue 0.59† 0.32 0.43 0.59† 0.60† 0.61† 0.64† 0.64†
Confusion/ bewilderment 0.36† 0.24 0.47† 0.49† 0.52† 0.41 0.52† 0.46†
Total mood disturbance 0.53† 0.37 0.67† 0.66† 0.72† 0.67† 0.74† 0.69†
EWB, Emotional Well-being; FACT-G, PWB þ SWB þ EWB þ FWB; FACT-Leu, FACT-G þ Leu subscale; FWB, Functional Well-being; GVHD, graft-
versus-host-disease; Leu ¼ Leukemia subscale; PWB, Physical Well-being; SWB, Social/Family Well-being; MCSDS, Marlowe-Crown Social
Desirability Scale; MRC/EORTC QLQ-LEU, Medical Research Council/European Organisation for Research and Treatment of Cancer Quality of
Life Questionnaire-Leukaemia; INFECT, Concerns surrounding infection; SENSLOSS, Sensory loss; POMS, Profile of Mood States;
TOI, trial outcome index, PWB þ FWB þ Leu subscale.
* P o 0.05.
† Po 0.01.
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Table 4 – FACT-Leu scale scores by patient-rated ECOG PSR at baseline.
Mean  SD F
(2,74)
P ES (PSR 1
vs. 0)
ES (PSR
2þ vs. 0)
ES (PSR
2þ vs. 1)
ECOG PSR 0
(n ¼ 35)
ECOG PSR 1
(n ¼ 30)
ECOG PSR 2þ
(n ¼ 13)
PWB 25.7  3.6 22.6  3.9 14.2  6.6 31.5 o0.001 0.772 1.882 1.229
SWB 24.5  5.3 22.5  5.7 21.5  5.1 1.8 0.164 0.366 0.543 0.181
EWB 19.5  3.6 19.1  3.8 15.4  4.2 5.5 0.006 0.110 0.970 0.896
FWB 22.7  5.1 19.6  3.9 11.6  4.5 26.3 o0.001 0.643 2.045 1.152
FACT-G 92.4  11.6 83.7  12.6 62.7  13.5 25.9 o0.001 0.681 1.865 1.180
Leu subscale 57.5  6.5 49.8  8.9 39.0  10.8 23.8 o0.001 0.901 1.752 0.964
FACT-Leu scale 150.1  16.9 133.5  19.8 101.7  21.6 29.8 o0.001 0.833 1.958 1.135
TOI 106.2  13.4 91.9  13.9 64.8  19.0 36.3 o0.001 0.931 2.103 1.150
ECOG PSR 0, Eastern Cooperative Oncology Group Performance Status Rating (normal activity, no symptoms); ECOG PSR 1, Eastern Cooperative
Oncology Group Performance Status Rating 1 (some symptoms, no bed rest); ECOG PSR 2þ, Eastern Cooperative Oncology Group Performance
Status Rating 2þ (some amount of bed rest); ES, effect size: difference divided by common SD; EWB, Emotional Well-being; FACT-Leu, FACT-G þ
Leu subscale; FWB, Functional Well-being; FACT-G, PWB þ SWB þ EWB þ FWB; Leu, Leukemia subscale; PWB, Physical Well-being; SWB, Social/
Family Well-being; TOI, trial outcome index ¼ PWB þ FWB þ Leu subscale.
VA L U E I N H E A LT H 1 5 ( 2 0 1 2 ) 1 0 5 1 – 1 0 5 81056with either acute or chronic leukemia. Although HRQOL is clearly
important in leukemia, a paucity of research has examined
leukemia-specific HRQOL outcomes in clinical trials [17].
The availability of efficient, targeted questionnaires with
representative questions may provide a useful tool to researchers
[16]. Patient-reported outcomes are becoming increasingly impor-
tant in research, clinical practice, and policy. In clinical trial and
other settings, it is desirable to obtain patient-reported data that
are highly specific to the condition under consideration, such as
leukemia. The development of an instrument such as the FACT-
Leu scale carries important implications for clinical research and
clinical practice. The availability of the FACT-Leu scale helps to fill
a need for reliable and valid measures of leukemia-specific
HRQOL for inclusion in clinical trials. Increased use of
leukemia-specific HRQOL assessment in clinical trials could
provide valuable information to help guide clinical decision
making [17], particularly in instances in which available treat-
ment options may not differ in terms of clinical outcomes but
may differ on HRQOL impact.
Internal consistency of the Leu subscale was very good at all
three assessments, as was its test-retest reliability, with the
intraclass correlation coefficient being 0.86. The subscale, and
the aggregated scores it rolls up into (trial outcomes index; FACT-
Leu scale total score), showed excellent concurrent validity with
regard to treatment status, performance status, and mood.
Participants who were not on treatment had better performanceTable 5 – FACT-Leu scale scores by treatment status at baseline
Mean  SD
Not on any treatment (n ¼ 48)
PWB 23.8  5.1
SWB 23.8  5.1
EWB 19.0  3.6
FWB 20.6  5.7
FACT-G 87.1  14.1
Leu subscale 53.7  9.4
FACT-Leu scale 140.9  21.9
TOI 98.2  18.3
EWB, Emotional Well-being; FACT-G, PWB þ SWB þ EWB þ FWB; FACT-Leu
subscale; PWB, Physical Well-being; SWB, Social/Family Well-being; TOI,status scores, better mood, and better scores on the relevant
FACT-Leu scale scores. Moreover, the FACT-Leu scale demon-
strated good responsiveness to change. Patients with declining
performance status reported worsening of their leukemia-
specific concerns. In contrast, those whose performance status
improved also reported improvements in their Leukemia sub-
scale scores.
We expected to produce separate forms for acute and chronic
disease; indeed, two-thirds of our experts thought we should.
Research and clinical training highlight, and often assume,
differences between acute and chronic subtypes of leukemia
[19]. Research, however, also points to overlap in the specific
areas of HRQOL affected by acute and chronic leukemia [16,34].
The patient-reported data from this study regarding content,
item importance, and priority showed that the most important
disease-related issues faced by patients with acute versus
chronic disease were far more similar than different. We there-
fore produced a common leukemia subscale. In the present study,
FACT-Leu scale scores did not differ significantly between indivi-
duals with acute leukemia and individuals with chronic leuke-
mia, supporting the notion that the questionnaire can be used to
assess leukemia-specific HRQOL among individuals with acute
lymphoblastic leukemia, chronic lymphocytic leukemia, and
chronic myeloid leukaemia. Given the relatively small sample
size in the present study, future validation in specific leukemia
subpopulations is warranted..
t (75) P
On treatment (n ¼ 30)
20.9  6.4 2.2 0.030
22.4  5.9 1.1 0.272
18.3  4.5 0.7 0.485
18.4  6.2 1.6 0.116
80.0  17.6 2.0 0.054
48.2  11.2 2.3 0.024
128.2  27.8 2.2 0.029
87.5  21.8 2.3 0.024
, FACT-G þ Leu subscale; FWB, Functional Well-being; Leu, Leukemia
trial outcome index ¼ PWB þ FWB þ Leu subscale.
Table 6 – FACT-Leu scale scores by disease type.
Mean  SD t (75) P
Chronic (n ¼ 44) Acute (n ¼ 34)
PWB 22.5  6.4 22.9  4.9 0.3 0.75
SWB 22.2  6.1 24.7  4.1 2.0 0.046
EWB 18.7  3.8 18.8  4.2 0.1 0.92
FWB 20.7  5.4 18.3  6.4 1.7 0.08
FACT-G 84.0  16.5 84.6  15.1 0.2 0.87
Leu subscale 51.2  11.5 52.1  9.0 0.4 0.72
FACT-Leu scale 135.2  26.4 136.8  23.5 0.3 0.79
TOI 94.4  21.5 93.4  18.9 0.2 0.84
EWB, Emotional Well-being; FACT-G, PWB þ SWB þ EWB þ FWB; FACT-Leu, FACT-G þ Leu subscale; FWB, Functional Well-being; Leu, Leukemia
subscale; PWB, Physical Well-being; SWB, Social/Family Well-being; TOI, trial outcome index ¼ PWB þ FWB þ Leu subscale.
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This study had some important limitations. The scale construc-
tion sample size (patients and providers) was international in
scope and ample with regard to actual numbers, given the usual
standards for scale development. Although we sampled patients
and experts from across three continents to ensure broad repre-
sentativeness, the number of patients in any one group is
insufficient to make conclusions about any subgroup. Neverthe-
less, the broad representativeness provides some reassurance
that a wide cultural range of content could be included. In
contrast to the scale construction sample, the validation sample
came entirely from one American city. This limits the potential
generalizability of the validation data. Further validation work
will be important to better ensure scale generalizability and
interpretation. It would be good to test the longer 27-item Leu
subscale in a patient population of sufficient size to replicate the
presence of a dominant single factor, further justifying the single
17-item score. Some might prefer to use the longer, 27-item Leu
subscale to further evaluate its validity, including content validity.
The 27-item version can be downloaded at http://www.facit.org.
It is important to consider the results of this study in light of
the ongoing developments in the treatment of acute and chronic
leukemia. Changes in leukemia treatment may change the HRQOL
issues faced by individuals with acute and chronic leukemia.
However, as this leukemia-specific subscale is focused primarily
on disease-related symptoms and concerns, the need to modify
content in the future is less likely than it would be if this wereTable 7 – Changes in FACT-Leu scale scores by change in patie
Mean  SD
PSR worsened (n ¼ 12) PSR unchanged
PWB 3.8  3.6 0.1  3.0
SWB 1.7  3.9 0.3  3.9
EWB 0.9  2.3 0.4  2.8
FWB 2.6  4.4 0.3  3.7
FACT-G 8.8  8.1 0.2  9.3
Leu subscale 4.8  5.7 0.3  6.8
FACT-Leu scale 13.3  26.4 1.0  14.
TOI 10.6  21.8 1.0  10.
EWB, Emotional Well-being; FACT-G, PWB þ SWB þ EWB þ FWB; FACT-Leu
subscale; PSR, Eastern Cooperative Oncology Group Performance Status R
trial outcome index ¼ PWB þ FWB þ Leu subscale.designed primarily as a measure of treatment burden from side
effects. The Functional Assessment of Chronic Illness Therapy
Measurement System includes treatment-relevant assessment
options for bone marrow transplantation, biologic response
modifier therapy, neutropenia, and anemia (http://www.facit.
org). These more treatment-focused subscales might be useful
additions to the FACT-Leu scale when a leukemia research ques
tion is focused on one or more of these treatment-related issues.
Both the scale construction and validation phases of the study
were restricted in focus to adults with leukemia. Consequently,
we do not recommend the use of this instrument in pediatric
leukemia populations. Future research is needed to address the
development of validated measures of HRQOL in children and
adolescents with leukemia.
Finally, although the validity data help verify that the Leu
subscale performs in the predicted, responsive manner, the data
are insufficient to enable stable estimates of minimally important
difference score or other similar interpretation aids. It is note-
worthy, however, that whether looking at average score differ-
ences by baseline performance status (Table 4), average score
changes by change in performance status (Table 7), or treatment
status (Table 5), FACT-Leu scale scores, and in particular the more
physically-oriented ones (including the Leu subscale), were quite
responsive to the selected anchors. ESs for difference and change
scores were mostly in the range of 0.5 to 1.0 (medium to large).
While likely to be larger than the minimally important difference,
these ESs bode well for the instrument’s responsiveness in this
population of patients.nt-rated ECOG PSR.
F (2,58) P
(n ¼ 41) PSR improved (n ¼ 8)
4.2  6.3 11.7 o0.001
0.1  3.2 1.3 0.284
2.4  3.3 3.9 0.025
3.1  8.2 3.7 0.031
9.7  18.8 6.8 0.002
7.4  8.7 7.4 0.001
1 17.0  26.4 8.6 o0.001
6 14.7  21.8 9.46 o0.001
, FACT-G þ Leu subscale; FWB, Functional Well-being; Leu, Leukemia
ating, PWB, Physical Well-being; SWB, Social/Family Well-being; TOI,
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